Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Neumann

Showing results (211-220 of 301) with videos related to

Pageof 31
Sort By:
Critical Care Medicine|April 16, 2019
Cost-Effectiveness Studies in the ICU: A Systematic ReviewM Elizabeth Wilcox, Kelsey Vaughan, Christopher A K Y Chong, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 22, 2022
The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case StudiesSiyu Ma, Natalia Olchanski, Joshua T Cohen, et al.
JAMA|July 23, 2002
Long-term persistence in use of statin therapy in elderly patientsJoshua S Benner, Robert J Glynn, Helen Mogun, et al.
BMJ (Clinical Research Ed.)|April 22, 2004
Delays in publication of cost utility analyses conducted alongside clinical trials: registry analysisDan Greenberg, Allison B Rosen, Natalia V Olchanski, et al.
Health Affairs (Project Hope)|February 4, 2015
Medicare is scrutinizing evidence more tightly for national coverage determinationsJames D Chambers, Matthew Chenoweth, Michael J Cangelosi, et al.
Health Research Policy and Systems|December 4, 2016
The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and BangladeshYot Teerawattananon, Sripen Tantivess, Inthira Yamabhai, et al.
Pharmacoeconomics|July 23, 2020
Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018David D Kim, Madison C Silver, Natalia Kunst, et al.
Pharmacoeconomics|October 22, 2020
Correction to: Perspective and Costing in Cost‑Effectiveness Analysis, 1974-2018David D Kim, Madison C Silver, Natalia Kunst, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2019
Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene TherapyMichael F Drummond, Peter J Neumann, Sean D Sullivan, et al.
The Milbank Quarterly|June 29, 2010
EBM, HTA, and CER: clearing the confusionBryan R Luce, Michael Drummond, Bengt Jönsson, et al.
Pageof 31

Showing results (211-220 of 301) with videos related to

Sort By:
Pageof 31
Critical Care Medicine|April 16, 2019
Cost-Effectiveness Studies in the ICU: A Systematic ReviewM Elizabeth Wilcox, Kelsey Vaughan, Christopher A K Y Chong, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 22, 2022
The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case StudiesSiyu Ma, Natalia Olchanski, Joshua T Cohen, et al.
JAMA|July 23, 2002
Long-term persistence in use of statin therapy in elderly patientsJoshua S Benner, Robert J Glynn, Helen Mogun, et al.
BMJ (Clinical Research Ed.)|April 22, 2004
Delays in publication of cost utility analyses conducted alongside clinical trials: registry analysisDan Greenberg, Allison B Rosen, Natalia V Olchanski, et al.
Health Affairs (Project Hope)|February 4, 2015
Medicare is scrutinizing evidence more tightly for national coverage determinationsJames D Chambers, Matthew Chenoweth, Michael J Cangelosi, et al.
Health Research Policy and Systems|December 4, 2016
The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and BangladeshYot Teerawattananon, Sripen Tantivess, Inthira Yamabhai, et al.
Pharmacoeconomics|July 23, 2020
Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018David D Kim, Madison C Silver, Natalia Kunst, et al.
Pharmacoeconomics|October 22, 2020
Correction to: Perspective and Costing in Cost‑Effectiveness Analysis, 1974-2018David D Kim, Madison C Silver, Natalia Kunst, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2019
Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene TherapyMichael F Drummond, Peter J Neumann, Sean D Sullivan, et al.
The Milbank Quarterly|June 29, 2010
EBM, HTA, and CER: clearing the confusionBryan R Luce, Michael Drummond, Bengt Jönsson, et al.
Pageof 31